Anti-LRRK2/Dardarin, C-Terminus Antibody (N241A/34)

Name: Anti-LRRK2/Dardarin, C-Terminus Antibody
Brand: NeuroMab
SKU: 75-253
Price: 374.0 USD
Availability: InStock

146 Citations

Our Anti-Dardarin/LRRK2, C-terminus mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N241A/34. It is KO validated, detects drosophila, human, mouse, non-human primate, and rat Dardarin/LRRK2, C-terminus, and is purified by Protein A chromatography. It is great for use in IHC, ICC, IP, ELISA, WB.

$Chemiluminescent immunoblot of endogenous LRRK2 (cat. 75-253) in cytoplasmic and membrane fractions of B16 melanocytes with Rab38 versus control siRNA knockdown. TFRC and GAPDH are used as membrane and cytoplasmic markers, respectively. Image from publication CC-BY-4.0. PMID:37625589$

Adult rat brain immunohistochemistry (with antigen retrieval via sodium citrate pretreatment).

Immunoblot versus crude membranes from adult rat brain (RBM) and wild-type (WT) and LRRK2 KO mouse brains probed with N241A/34 (left) and K89/41 (right) TC supe. Mouse brain samples provided by Xiaojie Li, Ted Dawson and Valina Dawson (Johns Hopkins University).

Representative Western blotting of total LRRK2, LRRK2-pSer935, pRab10, Rab10 total, and GAPDH levels following treating human peripheral blood mononuclear cells (PBMCs) with XL01126, a LRRK2 degrader, and cis-XL01126, a non-degrader control, at the indicated concentrations for 4 h. Image from publication CC-BY-4.0. PMID: 36007011

Chemiluminescent immunoblot of endogenous LRRK2 (cat. 75-253) in cytoplasmic and membrane fractions of B16 melanocytes with Rab38 versus control siRNA knockdown. TFRC and GAPDH are used as membrane and cytoplasmic markers, respectively. Image from publication CC-BY-4.0. PMID:37625589

Species Reactivity

Drosophila, Human, Mouse, Non-Human Primate, Rat

Applications

ELISA, ICC, IHC, IP, WB

Host Species

Mouse

Available Conjugates

490

550

594

650

Go to Full Product Details

Data Sheet

KO Validated

Trial Size

SKU: 75-253

Volume: 100 µL

Variant

Price:

$374.00

Quantity:

Product Details

Target

Dardarin/LRRK2, C-terminus

Target Description

LRRK2 (also known as PARK8) encodes a protein with 5 putative functional domains: an N-terminal leucine-rich repeat (LRR) domain, a Roc (Ras of complex protein) domain that shares sequence homology to the Ras-related GTPase superfamily, a COR (C-terminal of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) domain, and a C-terminal WD40 repeat domain. Mutation in this gene is one of the most common causes of inherited Parkinson disease (Gandhi et al., 2008). LRRK2 was originally identified as a putative disease-causing transcript (DKFZp434H2111) within a 2.6-Mb region encompassing a locus for Parkinson disease-8 (PARK8). Northern blot analysis detected a 9-kb mRNA transcript in all tissues tested, including brain. The authors named the protein product dardarin, derived from the Basque word dardara, meaning tremor. LRRK2/dardarin is also known to positively regulate autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway and together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. LRRK2/PARK8 is also known to regulate neuronal process morphology in the intact central nervous system (CNS) and play a role in synaptic vesicle trafficking.

Format

Purified by Protein A chromatography

Concentration

1 mg/mL

Clonality

Monoclonal

Clone

N241A/34

Isotype

IgG2a

Applications

ELISA, ICC, IHC, IP, WB

Host Species

Mouse

Gene Name

LRRK2 PARK8

Molecular Weight

>200 kDa

Antigen

Fusion protein amino acids 970-2527 (C-terminus) of human LRRK2 (accession number Q5SS00) produced recombinantly in E. Coli.

Species Reactivity

Drosophila, Human, Mouse, Non-Human Primate, Rat

Antibody Registry ID

AB_10675136

Storage

Aliquot and store at ≤ -20°C for long term storage. For short term storage, store at 2-8°C. For maximum recovery of product, centrifuge the vial prior to removing the cap.

Physical State

Liquid

Production Notes

Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody.

Buffer

10 mM Tris, 50 mM Sodium Chloride, 0.065% Sodium Azide pH 7.125

Dilution Ranges

WB: 1:1000
IHC: 1:500
ICC: 1:500

Conjugate

Unconjugated

Specificity

No cross-reactivity reported

Quality Control

Each new lot of antibody is quality control tested by western blot on rat whole brain lysate and confirmed to stain the expected molecular weight band.

Usage Statement

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Country of Origin

United States

Expiration

24 months from date of receipt

Shipping

Shipped on ice packs

Synonyms

Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)

UniProt Details

UniProt (Human): Q5S007
UniProt (Immunogen Species): Q5S007

Product Specific References for Applications and Species

ELISA: Human
Immunocytochemistry: Drosophila | Human | Mouse | Rat
Immunohistochemistry: Human | Mouse | Rat
Immunoprecipitation: Human | Mouse
PLA: Human | Mouse | Rat
Western Blot: Drosophila | Human | Mouse | Non-Human Primate | Rat
Additional Publications: Unspecified

ELISA: Human
PMID	Dilution	Publication
32652692	not listed	Melachroinou, K., et al. 2020. Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method. Movement Disorders, 2095-2100.
32523511	1 ug/ul	Mabrouk, O.S., et al. 2020. Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients. Frontiers in Neuroscience, .
32007961	1:10	Padmanabhan, S., et al. 2020. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts. NPJ Parkinson's Disease, 623-629.
30858560	not listed	Schaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329.

Immunocytochemistry: Drosophila
PMID	Dilution	Publication
34250948	not listed	Fellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820.

Immunocytochemistry: Human
PMID	Dilution	Publication
37384414	1:100	Williamson, MG, et al. 2023. Mitochondrial Dysfunction and Mitophagy Defects in LRRK2-R1441C Parkinson's Disease Models. Human molecular genetics, 0.
36905628	1:3 (supe)	Filippini, F., et al. 2023. Secretion of VGF Relies on the Interplay Between LRRK2 and Post-Golgi v-SNAREs. Cell Reports, 112221.
35599495	1:1000	Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
34604446	1:1000	Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.
34114604	1mg/ml	Calamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, .
32359446	not listed	Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
29472595	not listed	Antoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455.
26651604	not listed	Schwab, A.J., et al. 2015. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson''s Disease-Related LRRK2 G2019S Mutation.. Stem Cell Reports., 1039-1052.

Immunocytochemistry: Mouse
PMID	Dilution	Publication
35599495	1:50	Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
31663853	not listed	Berndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416.
29054882	1:500	Pan, P.Y., et al. 2017. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Journal of Neuroscience, 11366-11376.
28710481	1:100	Carrion, M.D.P., et al. 2017. The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Scientific Reports, 5377.
26365310	1:50	Choi, I., et al. 2015. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.. Nature Communication, 8255.

Immunocytochemistry: Rat
PMID	Dilution	Publication
35577065	1:1000	Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754.
24927544	not listed	Daher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294.

Immunohistochemistry: Human
PMID	Dilution	Publication
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.

Immunohistochemistry: Mouse
PMID	Dilution	Publication
33483550	1:600	Lebovitz, C., et al. 2021. Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Scientific Reports, 2097.
30927072	1:1000	Bieri, G., et al. 2019. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathologica Communications, 961-980.
27911006	1:100 - 1:400	Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432.
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Immunohistochemistry: Rat
PMID	Dilution	Publication
35577065	1:500	Keeney, M.T., et al. 2022. NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 105754.
33636387	1:500	De Miranda, B.R., et al. 2021. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Neurobiology of Disease, 105312.
24927544	not listed	Daher, J.P., et al. 2014. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.. PNAS: USA, 9289-9294.
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Immunoprecipitation: Human
PMID	Dilution	Publication
32359446	not listed	Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Immunoprecipitation: Mouse
PMID	Dilution	Publication
29212815	not listed	Purlyte, E., et al. 2018. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO Journal, 1-18.
24282027	not listed	Stafa, K., et al. 2014. Functional interaction of Parkinson''s disease-associated LRRK2 with members of the dynamin GTPase superfamily.. Human Molecular Genetics, 2055-2077.

PLA: Human
PMID	Dilution	Publication
34604446	1:500	Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.

PLA: Mouse
PMID	Dilution	Publication
35599495	1:1000	Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.

PLA: Rat
PMID	Dilution	Publication
34604446	1:500	Keeney, M.T., et al. 2021. Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol, e4140.

Western Blot: Drosophila
PMID	Dilution	Publication
34250948	not listed	Fellgett, A., et al. 2021. Multiple pathways of LRRK2-G2019S/Rab10 interaction in dopaminergic neurons.. Journal of Parkinson's Disease, 1805-1820.
34030727	1:200	Sarkar, S., et al. 2021. Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo. . Molecular Neurodegeneration, 44579.
32321836	1:1000	Petridi, S., et al. 2020. In vivo visual screen for dopaminergic Rab↔ LRRK2-G2019S interactions in Drosophila discriminates Rab10 from Rab3.. Genes, Genomes, Genetics, 1903-1914.
29214211	1:1000	Cording, A.C., et al. 2017. Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease. NPJ Parkinson's Disease, 34.

Western Blot: Human
PMID	Dilution	Publication
37141099	1:1000	Rinaldi, C., et al. 2023. Dissecting the Effects of GTPase and Kinase Domain Mutations on LRRK2 Endosomal Localization and Activity. Cell Reports, 112447.
36007011	1:1000	Liu, X., et al. 2022. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of American Chemical Society, .
35347144	1:1000	Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 Protein and Activity on Stimulated Cytokines in Human Monocytes and Macrophages. NPJ Parkinson's Disease, 34.
35347144	1:1000	Ahmadi Rastegar, D., et al. 2022. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinson's Disease, 34.
35326469	1ug/ml	Marchand, A., et al. 2022. A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively. Cells, 1018.
35016853	not listed	Cogo, S., et al. 2022. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain research, 147781.
34580980	1ug/ml	Waschbüsch, D., et al. 2021. Structural basis for the specificity of PPM1H phosphatase for Rab GTPases. EMBO Reports, e52675.
34515301	not listed	Tasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573.
34315807	not listed	Liu, Q., et al. 2021. Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration. Science Signaling, eabg3555.
34145320	1:500	Wang, X., et al. 2021. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Scientific Reports, 12900.
34125248	1ug/ml	Fan, Y., et al. 2021. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathologica Communications, 475-494.
34114604	1:1000	Calamini, B., et al. 2021. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease. Disease, Models, and Mechanisms, .
34008015	not listed	Cheung, M., et al. 2021. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 1750-1761.
33938021	not listed	Lai, D., et al. 2021. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.. Annals of Neurology, 76-88.
33887226	1:1000	Waschbüsch, D., et al. 2021. Dual arginine recognition of LRRK2 phosphorylated Rab GTPases. Biophysical Journal, 1846-1855.
33836114	not listed	Bright, J.M., et al. 2021. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. Movement Disorders, 1362-1371.
33197196	1:10,000	Garofalo, A.W., et al. 2021. Selective Inhibitors of G2019S-LRRK2 Kinase Activity. Journal of Medicinal Chemistry, 14821-14839.
33049313	not listed	Harney, J., et al. 2021. An in vitro alveolar epithelial cell model recapitulates LRRK2 inhibitor-induced increases in lamellar body size observed in preclinical models. Toxicology In Vitro, 105012.
33057100	1:200	Gonzalez-Hunt, C.P., et al. 2020. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. Scientific Reports, 17293.
32800998	1:1000	Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 105049.
32643832	not listed	Herbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494.
32461697	not listed	Whiffin, N., et al. 2020. The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 869-877.
32359446	not listed	Lee, H., et al. 2020. LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. Stem Cell Reports, 940-955.
32227113	not listed	Vieweg, S., et al. 2020. PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.. Biochemical Journal, 1651-1668.
32017888	1:1000	Waschbüsch, D., et al. 2020. Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure, 406-417.
30858560	not listed	Schaffner, A., et al. 2019. Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Research, 313-329.
30597610	1:1000	Atashrazm, F., et al. 2019. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disorders, 406-415.
30460108	not listed	Jang, J., et al. 2018. Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Animal Cells and Systems, 273-280.
29472595	not listed	Antoniou, N., et al. 2018. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway. Scientific Reports, 3455.
29357897	1:1000	Madero-Pérez, J., et al. 2018. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. . Molecular neurodegeneration, 44583.
29177506	not listed	Liu, Z., et al. 2018. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Human Molecular Genetics, 385-395.
29166931	not listed	Wang, S., et al. 2017. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathologica Communications, 86.
28860483	1:2000	Thirstrup, K., et al. 2017. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Scientific Reports, 10300.
26251043	not listed	Henry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028.
25939886	not listed	Zhao, J., et al. 2015. LRRK2 dephosphorylation increases its ubiquitination. Biochemical Journal, 107-120.
25080504	1:1000	Gómez-Suaga, P., et al. 2014. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.. Human Molecular Genetics, 6779-6796.
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
24427314	not listed	Dorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One, e85510.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
23065705	1:15,000	Yao, C., et al. 2013. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.. Human Molecular Genetics, 328-344.
22012985	not listed	Gómez-Suaga, P., et al. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP.. Human Molecular Genetics, 511-525.

Western Blot: Mouse
PMID	Dilution	Publication
37625589	not listed	Unapanta, A, et al. 2023. Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes. The Journal of Biological Chemistry, 105192.
37289222	not listed	Cabezudo, D, et al. 2023. Mutant LRRK2 Exacerbates Immune Response and Neurodegeneration in a Chronic Model of Experimental Colitis. Acta Neuropathologica, 245-261.
36040231	1:1000	Malik, A.U., et al. 2022. PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain. Biochemical Journal, .
35776681	1:1000	Lara Ordóñez, A.J., et al. 2022. The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization. Biology Open, .
35599495	1:1000	Fernández, B., et al. 2022. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease , 1423-1447.
35269482	1:400	Ho, D.H., et al. 2022. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells, 861.
35012605	not listed	Xu, E., et al. 2022. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular neurodegeneration, 7.
34759048	not listed	Kim, J.W., et al. 2021. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. eNeuro, .
34515301	not listed	Tasegian, A., et al. 2021. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. The Biochemical Journal, 3555-3573.
33459343	1:1000	Malik, A.U., et al. 2021. Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. . Biochemical Journal, 553-578.
33298972	1:1000	Wang, S., et al. 2020. Exosome markers of LRRK2 kinase inhibition. NPJ Parkinson's Disease, 32.
33135724	not listed	Kalogeropulou, A.F., et al. 2020. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. Biochemical Journal, 4397-4423.
32853409	not listed	Liu, Z., et al. 2020. LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. EMBO Journal, e104862.
32800998	1:1000	Zhao, Y., et al. 2020. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutatio. Neurobiology of Disease, .
32643832	not listed	Herbst, S., et al. 2020. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, e104494.
31881263	1:5 (supe)	Kofoed, R.H., et al. 2020. Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein. Neurobiology of Disease, 104720.
31663853	1:1000	Berndsen, K., et al. 2019. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife, e50416.
30949397	not listed	Ho, D.H., et al. 2019. G2019s LRRK2 promotes mitochondrial fission and increases TNFα-mediated neuroinflammation responses. Animal Cells and Systems, 106-111.
30592011	not listed	Ulusoy, A., et al. 2019. Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization. Molecular Neurobiology, 5273-5286.
30048714	1:2000	Kelly, K., et al. 2018. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition. Experimental Neurology, 1-13.
30022868	not listed	Ho, D.H., et al. 2018. LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation. Experimental Neurobiology, 171-180.
29743203	1ug/ml	Mir, R., et al. 2018. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochemical Journal, 1861-1883.
29088368	not listed	Nguyen, A.P.T., et al. 2018. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Human Molecular Genetics, 120-134.
29246723	not listed	Schapansky, J., et al. 2017. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. Neurobiology of Disease, 26-35.
27943591	1:500	Qin, Q., et al. 2017. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission. CNS Neuroscience and Therapeutics, 162-173.
27911006	1:1000	Dzamko, N., et al. 2017. LRRK2 levels and phosphorylation in Parkinson''s disease brain and cases with restricted Lewy bodies.. Movement Disorders, 423-432.
26251043	not listed	Henry, A.G., et al. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.. Human Molecular Genetics, 6013-6028.
25228699	not listed	Liu, Z., et al. 2014. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.. Journal of Biological Chemistry, 32937-32951.
24682598	not listed	Schapansky, J., et al. 2014. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.. Human Molecular Genetics, 4201-4214.
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
24427314	not listed	Dorval, V., et al. 2014. Gene and MicroRNA transcriptome analysis of Parkinson''s related LRRK2 mouse models.. PLoS One., e85510.

Western Blot: Non-Human Primate
PMID	Dilution	Publication
25653221	not listed	Fuji, R.N., et al. 2015. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.. Science Translastional Medicine, .

Western Blot: Rat
PMID	Dilution	Publication
38785531	1:100	Ho, DH, et al. 2024. Expression of G2019S LRRK2 in Rat Primary Astrocytes Mediates Neurotoxicity and Alters the Dopamine Synthesis Pathway in N27 Cells via Astrocytic Proinflammatory Cytokines and Neurotrophic Factors. Current Issues in Molecular Biology, 4324-4336.
35266954	not listed	Stormo, A.E., et al. 2022. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Journal of Cell Biology, e202010065.
34658337	1:1000	Khan, S.S., et al. 2021. Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain. Elife, e67900.
34306319	not listed	Ho, D.H., et al. 2021. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells. Oxidative Medicine and Cell Longevity, 9969842.
33600829	not listed	Kelly, K., et al. 2021. Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. Brain Research, 147372.
33594532	1:200	Van der Perren, A., et al. 2021. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo. Neurotherapeutics, 949-961.
32681050	1:2000	Østergaard, F.G., et al. 2020. Classification of α-synuclein-induced changes in the AAV α-synuclein rat model of Parkinson's disease using electrophysiological measurements of visual processing. Scientific Reports, 11869.
32631998	not listed	Nguyen, A.P.T., et al. 2020. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. PNAS: USA, 17296-17307.
31626293	not listed	Shani, V., et al. 2019. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Human Molecular Genetics, 3982-3996.
29307545	1:2000	Andersen, M.A., et al. 2018. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology, 15-22.
25904107	1:1000	Boddu, R., et al. 2015. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.. Human Molecular Genetics, 4078-4093.
25174649	1:1000	Lee, J.W., et al. 2015. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.. Neurobiol Aging, 505-518.
24633735	not listed	West, A.B., et al. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.. Journal of Comparative Neurology, 2465-2480.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Additional Publications: Unspecified
PMID	Publication
34144124	Drouyer, M., et al. 2021. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. . Neurobiology of Disease, 105426.
32250352	Fan, Y., et al. 2020. Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation. Journal of Visulized Experiments, .
31527116	Fernández, B., et al. 2019. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients. Biochemical Journal, 2797-2813.
31046837	Lee, J.H., et al. 2019. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes. Acta Neuropathologica Communications, 68.
30670570	Leandrou, E., et al. 2019. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes. Biochemical Journal, 559-579.
29519959	Kalogeropulou, A.F., et al. 2018. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity. Biochemical Journal, 1271-1293.
29127256	Lis, P., et al. 2018. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochemical Journal, 1-22.
29125462	Steger, M., et al. 2017. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife, e31012.
29023112	Williamson, D.S., et al. 2017. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of Medicinal Chemistry, 8945-8962.
28973664	Howlett, E.H., et al. 2017. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. Human Molecular Genetics, 4340.
28321439	Xiong, Y., et al. 2017. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro, .
28115417	Kim, M.J., et al. 2017. The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics, 729-741.
27503089	Perera, G., et al. 2016. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 31391.
27297049	Fraser, K.B., et al. 2016. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 1543-1550.
26865512	Fraser, K.B., et al. 2016. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology, 994-999.

Recover password

Create my account

Anti-LRRK2/Dardarin, C-Terminus Antibody (N241A/34)

SKU: 75-253

Product Details

Product Specific References for Applications and Species

Bulk Order Anti-LRRK2/Dardarin, C-Terminus Antibody

Related Products

Recently Viewed